KURA
Kura Oncology IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$779.07M
P/E Ratio
—
EPS
$-3.18
Beta
0.24
52W High
$12.49
52W Low
$5.45
50-Day MA
$8.39
200-Day MA
$8.62
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
0.00
About Kura Oncology Inc
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops drugs for the treatment of cancer in the United States. The company is headquartered in San Diego, California.
Fundamentals
| Revenue (TTM) | $67.48M |
| Gross Profit (TTM) | $-183.65M |
| EBITDA | $-302.60M |
| Operating Margin | -497.60% |
| Return on Equity | -94.80% |
| Return on Assets | -25.30% |
| Revenue/Share (TTM) | $0.77 |
| Book Value | $1.98 |
| Price-to-Book | 4.37 |
| Price-to-Sales (TTM) | 11.54 |
| EV/Revenue | 1.685 |
| EV/EBITDA | -2.48 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -67.80% |
| Shares Outstanding | $88.33M |
| Float | $64.78M |
| % Insiders | 2.12% |
| % Institutions | 97.72% |
Analyst Ratings
Consensus ($31.82 target)
2
Strong Buy11
Buy1
HoldData last updated: 4/8/2026